Thermographic evaluation of piroxicam’s effect as an adjuvant treatment in canine mammary tumors

Mammary tumors are the second most diagnosed neoplasms in dogs. Canine females are largely affected by malignant mammary tumours. Several factors are involved in the development and determination of the malignancy of these lesions, including the action of cyclooxygenase-2. Use of non-steroidal anti-...

ver descrição completa

Detalhes bibliográficos
Autores: Greghi, Julia Rodrigues, Fernandes, Maíra Planzo, Groth, Aline, Silva, Letícia Amanda dos Santos, Schnitzer, Josiana de Fátima, Di Santis, Giovana Wingeter, Martins, Maria Isabel Mello
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Brasil
Recursos:Universidade Federal de Itajubá (UNIFEI)
Repositorio:Research, Society and Development
Idioma:portugués
OAI Identifier:oai:ojs.pkp.sfu.ca:article/12236
Acesso em linha:https://rsdjournal.org/index.php/rsd/article/view/12236
Access Level:acceso abierto
Palavra-chave:Perros
Oncología
Inflamación
Glándula Mamaria
Inhibidores COX-2.
Canino
Oncologia
Glândulas Mamárias
Inflamação
Inibidores COX-2.
Canine
Oncology
Inflammation
Mammary Gland
COX-2 Inhibitors.
Descrição
Resumo:Mammary tumors are the second most diagnosed neoplasms in dogs. Canine females are largely affected by malignant mammary tumours. Several factors are involved in the development and determination of the malignancy of these lesions, including the action of cyclooxygenase-2. Use of non-steroidal anti-inflammatory drugs as enzyme-inhibiting drugs has been studied as a promising adjuvant treatment for neoplasms. The aim of this study was to evaluate the effect of piroxicam in reducing inflammation caused by mammary tumours in 25 bitches during 10 days of administration based on the measurement of peritumoral temperature using thermography. The results indicated a significant difference (p=0,003) between the average temperatures at the first and last day of treatment. When performing the evaluation of malignant and benign neoplasms separately, it was possible to observe that, statistically, malignant neoplasms (n=19) showed a significant reduction in peritumoral temperatures (P=<0.001), however, benign neoplasms (n=6) have not obtained a significant difference in temperature after the therapeutic protocol (P=0.954). Therefore, it was possible to demonstrate the efficacy of the medication in reducing the heat caused by inflammation and allowing advances in the development of therapeutic protocols for mammary tumors in bitches, such as the inclusion of the drug in the period prior to the mastectomy surgeries.